Cat. No.: HY-B0693

Ranitidine

4 Cited Publications

Customer Review

Based on 4 publication(s) in Google Scholar

Ranitidine is a potent, selective and orally active histamine H2-receptor antagonist that inhibits gastric secretion. Ranitidine antagonizes Histamine (HY-B1204)-induced increases of the guinea-pig isolated rat atrium and Histamine-induced relaxations of the rat isolated uterine horn, with pA₂ values of 7.2 and 6.95, respectively. Ranitidine inhibits breast tumor development and spread in mice.

For research use only. We do not sell to patients.

Purity: 99.9%
CAS No.: 66357-35-5
Formula: C₁₃H₂₂N₄O₃S
Molecular Weight:314.40

Storage:

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Ranitidine Chemical Structure

CAS No.: 66357-35-5

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vivo
Chemical Information
Publications (4)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]^[2]

H₂ Receptor

All Histamine Receptor Isoforms :

In Vivo

Ranitidine (0.03-3 mg/kg; i.v.; once) inhibits Histamine (HY-B1204)- and Pentagastrin (HY-A0261)-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat^[1].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) reduces the number of CD11b⁺Ly6C^hi cells in the spleen and bone marrow of BALB/c mice^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; treatment for 8 days) inhibits lung metastasis in BALB/c mice bearing 4T1 breast cancer^[2].
Ranitidine (8 mg/kg; oral administration; administered every other day; for 14 days) inhibits primary tumor growth in the E0771 breast cancer model of C57BL/6 mice^[2].
Ranitidine (dose enabling mice to ingest 6-8 mg/kg per day; added to drinking water; changed every 3 days; treatment starting from weaning (~4 weeks) until the end of the experiment (23-26 weeks)) increases the latency of breast tumorigenesis and reduces the number of tumors in LKB1^-/-NIC mice^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female Wistar rats (100 to 120 g) were anaesthetized with sodium pentobarbitone (50 mg/kg i.p.), and intravenous with Histamine (100 μg/kg/min) or Pentagastrin (1 μg/kg/min)^[1].
Dosage:

0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 0.6 mg/kg, 1 mg/kg, 3 mg/kg
Administration:

i.v.; once
Result:

Inhibited Histamine- and Pentagastrin-induced gastric acid secretion in the perfused stomach preparation of the anaesthetized rat.

Animal Model:

BALB/c female mice (5-6-8 week old), orthotopic breast cancer model by injecting 100,000 4T1 cells subcutaneously into the mammary fat pad near the fourth nipple^[2].
Dosage:

8 mg/kg
Administration:

Oral administration, every other day, 8 days
Result:

Decreased the proportion of CD11b⁺Ly6C^hi monocytic cells in the spleen and inhibited lung metastasis.

Animal Model:

C57BL/6 female mice (6-8 week old), orthotopic breast cancer model by injecting 200,000 E0771 cells in 100 μL of Matrigel subcutaneously into the mammary fat pad near the fourth nipple^[2].
Dosage:

8 mg/kg
Administration:

Oral administration, every other day, 8 days
Result:

Decreased primary tumor growth starting from approximately day 13 post-tumor cell injection.

Animal Model:

LKB1^-/-/NIC female mice (weaned at about 4 weeks old), spontaneous tumor development model starting from weaning^[2].
Dosage:

6-8 mg/kg
Administration:

Oral administration, every 3 days, from weaning until the end of the experiment
Result:

Increased the latency of tumorigenesis by an additional 24 days and reduced the average number of tumors per mouse.

Chemical Information

CAS No. 66357-35-5
Appearance Solid
Molecular Weight 314.40
Formula C₁₃H₂₂N₄O₃S
Color White to light brown
SMILES

O=[N+](/C=C(NC)/NCCSCC1=CC=C(CN(C)C)O1)[O-]
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Publications (4)

All

Sort by:

Journal Impact Factor

Cell Host Microbe

Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]

2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313
Brain Sci

Paraventricular Mast Cell-Derived Histamine Activates CRH Neurons to Mediate Adult Visceral Hypersensitivity Induced by Neonatal Maternal Separation. [Abstract]

2023 Nov 16;13(11):1595. PMID: 38002554
Indian J Ophthalmol

Ranitidine protects Müller cells against ferroptosis in diabetic retinopathy by regulating the AKT1/GSK3β pathway. [Abstract]

2026 Feb 1;74(2):250-258. PMID: 41581041
Kingston University

2026.

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (318.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.1807 mL

15.9033 mL

31.8066 mL

5 mM

0.6361 mL

3.1807 mL

6.3613 mL

10 mM

0.3181 mL

1.5903 mL

3.1807 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Daly MJ, et al. Some in vitro and in vivo actions of the new histamine H2-receptor antagonist, ranitidine. Br J Pharmacol. 1981 Jan;72(1):49-54. [Content Brief]

[2]. Vila-Leahey A, et al. Ranitidine modifies myeloid cell populations and inhibits breast tumor development and spread in mice. Oncoimmunology. 2016 Mar 10;5(7):e1151591. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.1807 mL	15.9033 mL	31.8066 mL	79.5165 mL
	5 mM	0.6361 mL	3.1807 mL	6.3613 mL	15.9033 mL
	10 mM	0.3181 mL	1.5903 mL	3.1807 mL	7.9517 mL
	15 mM	0.2120 mL	1.0602 mL	2.1204 mL	5.3011 mL
	20 mM	0.1590 mL	0.7952 mL	1.5903 mL	3.9758 mL
	25 mM	0.1272 mL	0.6361 mL	1.2723 mL	3.1807 mL
	30 mM	0.1060 mL	0.5301 mL	1.0602 mL	2.6506 mL
	40 mM	0.0795 mL	0.3976 mL	0.7952 mL	1.9879 mL
	50 mM	0.0636 mL	0.3181 mL	0.6361 mL	1.5903 mL
	60 mM	0.0530 mL	0.2651 mL	0.5301 mL	1.3253 mL
	80 mM	0.0398 mL	0.1988 mL	0.3976 mL	0.9940 mL
	100 mM	0.0318 mL	0.1590 mL	0.3181 mL	0.7952 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Ranitidine

Bioactive Compound Library Max

Bioactive Compound Library

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Neuronal Signaling Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

NMPA-Approved Drug Library

Orally Active Compound Library

Neurotransmitter Receptor Compound Library

FDA Approved & Pharmacopeial Drug Library

Anti-Breast Cancer Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Rare Diseases Drug Library

Pediatric Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Coagulation and Anti-coagulation Compound Library

Heterocyclic Compound Library

Withdrawn Drug Compound Library

Off-patent Drug Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

High-Throughput Bioactive Compound Library

Nephrotoxicity Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Ranitidine

All Histamine Receptor Isoforms

Biological Activity

Chemical Information

Publications (4)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Ranitidine Related Classifications

HY-B0693 Related Classifications